AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01822496
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg, orally, once daily for four 3-week cycles (12 weeks in total)
Trial: NCT01822496
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/m2, IV, on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, etoposide will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
Trial: NCT01822496
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable.~Consolidation: 4-6 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22.
Trial: NCT03793868
Drug: Perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral tablet
Trial: NCT03348384
Drug: NOP-1A
RxNorm normalized name: NOP-1A
DrugBank: NOP-1A (DB15208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tracer
Trial: NCT03555890
Drug: Levocetirizine ODT 5 mg
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levocetirizine ODT will be available as oral disintegrating tablet. Subjects will receive a single dose of 5 mg levocetirizine ODT. In Part 1, subjects will receive levocetirizine ODT with 150 mL water and in Part 2 subjects will receive levocetirizine ODT without water.
Trial: NCT03192878
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: infliximab biosimilar
Trial: NCT01213355
Drug: Scopolamine
RxNorm normalized name: Scopolamine
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injectable subcutaneous formulation, single dose, 1 day
Trial: NCT01213355
Drug: PF-05212377
RxNorm normalized name: PF-05212377
DrugBank: PF-05212377 (DB16044)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg, PF-05212377, capsule, single dose, 1 day
Trial: NCT01213355
Drug: PF-05212377
RxNorm normalized name: PF-05212377
DrugBank: PF-05212377 (DB16044)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg, capsule PF-05212377, single dose, 1 day
Trial: NCT01213355
Drug: scopolamine
RxNorm normalized name: Scopolamine
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injectable subcutaneous formulation, single dose, 1 day
Trial: NCT01213355
Drug: PF-05212377
RxNorm normalized name: PF-05212377
DrugBank: PF-05212377 (DB16044)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg PF-05212377, capsule, single dose, 1 day
Trial: NCT01213355
Drug: scopolamine
RxNorm normalized name: Scopolamine
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injectable sub cutaneous formulation, single dose, 1 day
Trial: NCT01213355
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, 10mg, single dose, 1 day
Trial: NCT01213355
Drug: Scopolamine
RxNorm normalized name: Scopolamine
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injectable sub cutaneous formulation, single dose, 1 day
Trial: NCT01375010
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg QD
Trial: NCT01375010
Drug: Vitamin Supplements
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).
Trial: NCT02082912
Drug: D-cycloserine
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-cycloserine 100mg PO twice weekly (Monday and Wednesday) for three weeks
Trial: NCT03347708
Drug: Saline Solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Chloride Solution
Trial: NCT03347708
Drug: Sodium Hyaluronate
RxNorm normalized name: sodium hyaluronate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Hyaluronate Vehicle
Trial: NCT02459652
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: S-1 is administered orally at a dose of 40 mg/m2 twice daily on the day of irradiation (Monday through Friday) during radiation therapy.
Trial: NCT04245371
Drug: Lidocaine 1.8%
RxNorm normalized name: LIDOCAINE 1.8% PATCH
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical Patch
Trial: NCT02024438
Drug: monosialotetrahexosylganglioside Sodium
RxNorm normalized name: Monosialotetrahexosylganglioside
DrugBank: Ganglioside GM1 (DB16948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: it is extracted from pig's brain,shenjie is the brand name
Trial: NCT02266706
Drug: Ceftolozane/Tazobactam 1000/500 mg
DrugBank: Tazobactam (DB01606)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A fixed dose combination (FDC) of 1000 mg ceftolozane and 500 mg tazobactam as a 60 minute infusion.
Trial: NCT02266706
Drug: Ceftolozane/Tazobactam 30/15 mg/kg
DrugBank: Tazobactam (DB01606)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A FDC of 30 mg/kg of ceftolozane and 15 mg/kg of tazobactam as a 60 minute infusion.
Trial: NCT02266706
Drug: Ceftolozane/Tazobactam 20/10 mg/kg
DrugBank: Tazobactam (DB01606)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A FDC of 20 mg/kg of ceftolozane and 10 mg/kg of tazobactam as a 60 minute infusion.
Trial: NCT02266706
Drug: Ceftolozane/Tazobactam 18/9 mg/kg
DrugBank: Tazobactam (DB01606)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A FDC of 18 mg/kg of ceftolozane and 9 mg/kg of tazobactam as a 60 minute infusion.
Trial: NCT02266706
Drug: Ceftolozane/Tazobactam 12/6 mg/kg
DrugBank: Tazobactam (DB01606)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A FDC of 12 mg/kg of ceftolozane and 6 mg/kg of tazobactam as a 60 minute infusion.
Trial: NCT00920205
Drug: MPC-3100 (an Hsp90 inhibitor)
RxNorm normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral daily dose for 21 days in a 28-day cycle
Trial: NCT01049399
Drug: tideglusib
RxNorm normalized name: Tideglusib
DrugBank: Tideglusib (DB12129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg of tideglusib as a powder for oral suspension once daily in fasting conditions for 52 weeks
Trial: NCT01049399
Drug: tideglusib
RxNorm normalized name: Tideglusib
DrugBank: Tideglusib (DB12129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of tideglusib as a powder for oral suspension, administered once daily in fasting conditions for 52 weeks
Trial: NCT02298504
Drug: Mineral Trioxide Aggregate
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vital pulp therapy
Trial: NCT03673384
Drug: Fluticasone Furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: used to treat seasonal and perennial allergic rhinitis. It also helps to reduce the symptoms of seasonal allergic rhinitis.
Trial: NCT03242824
Drug: Fluorine F 18 Fluorodopa
RxNorm normalized name: FLUORODOPA F-18
DrugBank: Fluorodopa (18F) (DB13848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Contrast used in PET
Trial: NCT02750943
Drug: Stannous Fluoride
RxNorm normalized name: Stannous Fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dentifrice containing 0.454% w/w stannous fluoride
Trial: NCT02750943
Drug: Sodium Monofluorophosphate
RxNorm normalized name: Sodium Monofluorophosphate
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dentifrice containing 1000ppm fluoride as sodium monofluorophosphate
Trial: NCT00003637
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04058678
Drug: Danazol/Placebo
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This group will be randomized 1:1 for either inactive substance or Danazol, according to a computer-generated randomization list prepared. Women will be treated with Danazol/Placebo oral way for 3 months.
Trial: NCT02906371
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients with ≥ 40% blasts in the bone marrow at pre-infusion will be enrolled in the early tocilizumab cohort and will follow early CRS treatment algorithm.
Trial: NCT02906371
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients with ˂ 40% blasts in the bone marrow at pre-infusion (\~ Day -5 to -1) will follow the standard CRS Rx algorithm
Trial: NCT03903653
Drug: Botulinum toxin type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Use of chemodenervation (botulinum toxin A) for treatment of lower extremity spasticity in ABI inpatients with regards to ankle range of motion.~(a total of 350-400 units of botulinum toxin A per treated limb)
Trial: NCT01467583
Drug: Fondaparinux
RxNorm normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg every 48 hours
Trial: NCT05309590
Drug: Dose
RxNorm normalized name: iDose
DrugBank: Zabedosertib (DB18767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The outcomes of reducing to half of the topical steroid (i.e. fluticasone \[Flovent\] and Swallowed viscous budesonide \[Pulmicort\]) will be observed with regards to whether the patients continue to be in histologic remission. These patients will have already achieved remission on a full dose of the steroid.
Trial: NCT00040261
Drug: Memantine HCL
RxNorm normalized name: memantine HCl
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01260571
Drug: Benzoyl peroxide and sulfur
RxNorm normalized name: Benzoyl peroxide and sulfur only product
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical cream, 5% benzoyl peroxide and 2% sulfur Frequency once to day Duration 24 hours
Trial: NCT02092961
Drug: Fostamatinib
RxNorm normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fostamatinib 100mg twice daily.
Trial: NCT02092961
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab 40 mg by subcutaneous injection every 2 weeks for 24 weeks.
Trial: NCT02092961
Drug: Placebo of Fostamatinib
RxNorm normalized name: fostamatinib
DrugBank: Tamatinib (DB07159)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Placebo bid for 6 weeks.
Trial: NCT02092961
Drug: Placebo of Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo injection once every two weeks.
Trial: NCT02270983
Drug: Linaclotide 145 micrograms
RxNorm normalized name: linaclotide
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02270983
Drug: Linaclotide 290 micrograms
RxNorm normalized name: linaclotide
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02301780
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants who are screened with a high-risk of developing PET will be randomised into one of 2 arms of the trial (on the same day as screening or within 1 week of the screening visit). Randomised participants will be advised to start 150mg of Aspirin/Placebo once per night within 24 hours of randomisation until 36 weeks' gestation or when signs of labour commence.~The maximum duration for aspirin or placebo intake will be 180 days.
Trial: NCT03239964
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: the wound edges are injected once with dexamethasone. A 1 mL syringe with a 30-gauge needle is used and injection is both intradermal and subdermal. Repeated alternate punctures are used to bathe the wound edges with the drug. Approximately 0.5-1 mL of dexamethasone (4 mg/mL) in wound tissue.
Trial: NCT00558727
Drug: RH-1
RxNorm normalized name: RH-1
DrugBank: RH-1 (DB04090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/m2 to 12 mg/m2, depending on protocol cohort, administered via intravenous (IV) infusion over 3 hours once every 21 days.
Trial: NCT00226694
Drug: Citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
Trial: NCT00854620
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib administered in escalating 28-days cycles (400, 600 and 800 mg BID)
Trial: NCT01394562
Drug: Ferinject (ferric carboxymaltose)
RxNorm normalized name: epinephrine
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive ferric carboxymaltose intravenously on Day 0, Week 6, and Week 12
Trial: NCT03517982
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Film Coated Tablet, each tablet contains 500mg Mycophenolate Mofetil
Trial: NCT00443950
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02294773
Drug: Clomiphene
RxNorm normalized name: Clomiphene
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient is to take clomiphene citrate during cycle days 3-7.
Trial: NCT02610361
Drug: BGB-283
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the dose escalation part(phase 1a): the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In dose expansion phase(Phase 1b): Patients will be assigned to different groups based on their tumor types
Trial: NCT02294773
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient is to take letrozole during cycle days 3-7.
Trial: NCT02002611
Drug: Lobeglitazone
RxNorm normalized name: lobeglitazone
DrugBank: Lobeglitazone (DB09198)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02002611
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03858478
Drug: Biktarvy arm
RxNorm normalized name: Biktarvy
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: BIKTARVY : one tablet QD, every day between D0 and M12 includind - TAF (25mg) / FTC (200mg) / BICTEGRAVIR (50mg)
Trial: NCT01981759
Drug: D-Cycloserine
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 10 administrations of 50 mg of D-Cycloserine by mouth one hour before CBT sessions, weekly, in weeks 3-12.
Trial: NCT01797419
Drug: GS-5806
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose, oral liquid, .5 mL/kg
Trial: NCT01147458
Drug: PF-04191834
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
Trial: NCT04137289
Drug: BI 905711
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 905711
Trial: NCT03739853
Drug: Sulfasalazine
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Used in arm 2 of study
Trial: NCT02199860
Drug: SD II
RxNorm normalized name: Alphanine SD
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03384693
Drug: Defibrotide
RxNorm normalized name: Defibrotide
DrugBank: Defibrotide (DB04932)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Defibrotide is an anticoagulant and fibrinolytic agent that has been shown to be an effective treatment in other endothelial disorders such as hepatic veno-occlusive disease.
Trial: NCT03739853
Drug: Leflunomide
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Used in arm 2 of study
Trial: NCT03739853
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Used in arm 3 of the study only
Trial: NCT03051282
Drug: Enalapril
RxNorm normalized name: Enalapril
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study participants in both arms will be treated with 10 mg enalapril orally once daily for seven consecutive days
Trial: NCT04086264
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Commercially available formulation given subcutaneously (SC) or intravenous (IV)
Trial: NCT04086264
Drug: IMGN632
RxNorm normalized name: IMGN632
DrugBank: IMGN632 (DB17337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study formulation given intravenously (IV)
Trial: NCT04086264
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Commercially available formulation administered orally
Trial: NCT02857361
Drug: Sublingual ketamine wafers
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two sublingual ketamine 25 mg wafers
Trial: NCT04478123
Drug: Romiplostim
RxNorm normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Romiplostim 3.0 mcg/kg SC on Day +1 and Romiplostim 2.0 mcg/kg SC on Day +8 after HDT-AHCT. Beyond Day +8, patients will be treated weekly until platelet count is \>50,000/mcL, without any platelet transfusions in the prior 48 hours. All doses after the second Romiplostim dose will be titrated as per Table 3, based on weekly CBC/platelet counts. Patients will receive a maximum of six weekly doses of romiplostim.
Trial: NCT00463203
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg/kg every 2 weeks
Trial: NCT00463203
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 125 mg/m2 non-EIAED or 340 mg/m2 EIAED every 2 weeks
Trial: NCT00353938
Drug: 3,4-methylenedioxymethamphetamine (125 mg)
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive an initial dose of 125 mg MDMA orally and, if investigator and participant deem appropriate, 2.5 hours later they will receive 62.5 mg MDMA orally.
Trial: NCT00838500
Drug: Immediate spa treatment
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1st year, soon after randomization: Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts(walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower...)
Trial: NCT00838500
Drug: Late spa treatment
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2nd year, soon after 12 months visit: Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts(walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower...)
Trial: NCT00145756
Drug: low sodium high potassium salt substitute
RxNorm normalized name: Low-Substituted Hydroxypropyl Cellulose
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03595709
Drug: 3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg)
RxNorm normalized name: mepivacaine
DrugBank: Mepivacaine (DB00961)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All eligible subjects will receive 3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg) once daily for 24 weeks orally on empty stomach before bedtime. If the event of toxicity or tolerability issues requires a change from study drug, switching to the best available treatment will be recommended.
Trial: NCT04039347
Drug: Liposomal Cyclosporine A 5 mg
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: delivered via the PARI eFlow® device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
Trial: NCT04039347
Drug: Liposomal Cyclosporine A 10 mg
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: delivered via the PARI eFlow® device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
Trial: NCT01605461
Drug: BI 207127 NA
RxNorm normalized name: bis(1-methylamyl) sodium sulfosuccinate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral solution dose of BI 207127 NA combined with \[14C\]-BI 207127 NA